REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL

Takeda Pharmaceutical CoAnnouncement

20/11/2018 09:45

RNS Number : 8934H
Morgan Stanley
20 November 2018
 


 
FORM 8.5 (EPT/NON-RI)
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 




(a) Name of exempt principal trader:


Morgan Stanley MUFG Securities Co., Ltd.




(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
     Use a separate form for each offeror/offeree


Takeda Pharmaceutical Company Limited




(c) Name of the party to the offer with which exempt principal trader is connected:


Shire plc




(d) Date position held/dealing undertaken:
     For an opening position disclosure, state the latest practicable date prior to the disclosure


19 NOVEMBER 2018




(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
     If it is a cash offer or possible cash offer, state "N/A"


YES - Shire plc




 
2.         POSITIONS OF THE EXEMPT PRINCIPAL TRADER                            
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 




 
Class of relevant security:


 
Ordinary




 
 


Interests


Short positions




Number


%


Number


%




(1) Relevant securities owned and/or controlled:


11,573,723


1.48


30,052,937


3.83




(2) Cash-settled derivatives:
 


29,606,409


3.78


10,830,771


1.38




(3) Stock-settled derivatives (including options) and agreements to purchase/sell:


185,000


0.02


185,000


0.02




 
     TOTAL:


41,365,132


5.28


41,068,708


5.23




 
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b)        Rights to subscribe for new securities (including directors' and other employee options)
 




Class of relevant security in relation to which subscription right exists:


N/A




Details, including nature of the rights concerned and relevant percentages:


N/A




 
 
3.         DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales
 




Class of relevant security


 Purchases/sales


 Total   number of securities


 Highest price per unit paid/received


 Lowest price per unit paid/received




 Ordinary


 PURCHASES


 1,255,526


 4,463.0000 JPY


 4,335.0000 JPY




 Ordinary


 SALES


 1,318,026


 4,464.0000 JPY


 4,337.0000 JPY




 
 (b)       Cash-settled derivative transactions
 




Class of relevant security


 Product description
            e.g. CFD


 Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position


 Number of reference securities


 Price per unit




Ordinary


CFD


LONG


3300


4430.2051 JPY




Ordinary


CFD


LONG


4600


4427.6739 JPY




Ordinary


CFD


SHORT


800


4354.0000 JPY




Ordinary


CFD


SHORT


400


4447.0000 JPY




Ordinary


CFD


LONG


400


4343.0000 JPY




Ordinary


CFD


SHORT


31000


4365.7322 JPY




Ordinary


CFD


LONG


62600


4389.9728 JPY




Ordinary


CFD


SHORT


4400


4380.2272 JPY




Ordinary


CFD


LONG


300


4343.0000 JPY




Ordinary


CFD


SHORT


21100


4376.8436 JPY




Ordinary


CFD


LONG


22200


4384.8558 JPY




Ordinary


CFD


LONG


100


4451.0000 JPY




Ordinary


CFD


LONG


700


4367.3057 JPY




Ordinary


CFD


LONG


1900


4367.3057 JPY




Ordinary


CFD


LONG


10400


4377.3008 JPY




Ordinary


CFD


SHORT


200


4384.0000 JPY




Ordinary


CFD


LONG


500


4390.4000 JPY




Ordinary


CFD


SHORT


500


4451.0000 JPY




Ordinary


CFD


LONG


1100


4362.5454 JPY




Ordinary


CFD


SHORT


4300


4436.4830 JPY




Ordinary


CFD


LONG


200


4343.4176 JPY




Ordinary


CFD


LONG


24700


4343.4176 JPY




Ordinary


CFD


SHORT


15100


4451.0000 JPY




Ordinary


CFD


SHORT


100


4395.0000 JPY




Ordinary


CFD


LONG


2000


4450.4500 JPY




Ordinary


CFD


SHORT


2600


4451.0000 JPY




Ordinary


CFD


LONG


1000


4372.0000 JPY




Ordinary


CFD


SHORT


1000


4372.0000 JPY




Ordinary


CFD


SHORT


900


4370.7777 JPY




Ordinary


CFD


LONG


1300


4420.7200 JPY




Ordinary


CFD


LONG


3800


4420.7200 JPY




Ordinary


CFD


SHORT


7400


4303.6756 JPY




Ordinary


CFD


LONG


7500


4299.6933 JPY




Ordinary


CFD


LONG


89300


4451.0000 JPY




Ordinary


CFD


SHORT


89300


4451.0000 JPY




Ordinary


CFD


SHORT


4900


4393.5821 JPY




Ordinary


CFD


LONG


20000


4447.8088 JPY




Ordinary


CFD


SHORT


20000


4425.1850 JPY




Ordinary


CFD


SHORT


23100


4451.0000 JPY




Ordinary


CFD


LONG


23100


4451.0000 JPY




Ordinary


CFD


SHORT


50000


4401.6700 JPY




Ordinary


CFD


SHORT


281400


4403.2299 JPY




Ordinary


CFD


LONG


174000


4410.8637 JPY




Ordinary


CFD


LONG


50000


4401.6700 JPY




Ordinary


CFD


LONG


127000


4343.0000 JPY




 
 (c)       Stock-settled derivative transactions (including options)               
 
(i)         Writing, selling, purchasing or varying
 




Class of relevant security


 Product description             e.g. call option


 Writing, purchasing, selling, varying etc.


 Number of securities to which option relates


 Exercise price per unit


 Type   e.g. American, European etc.


 Expiry date


 Option money paid/ received per unit




 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A




 
(ii)        Exercise
 




Class of relevant security


Product description
e.g. call option


Exercising/ exercised against


Number of securities


Exercise price per unit




N/A


N/A


N/A


N/A


N/A




 
(d)        Other dealings (including subscribing for new securities)
 




Class of relevant security


Nature of dealing
e.g. subscription, conversion


Details


Price per unit (if applicable)




N/A


N/A


N/A


N/A




 
 
4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 




Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"




 
None
 




 
(b)        Agreements, arrangements or understandings relating to options or derivatives
 




Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"




 
None
 




 
(c)        Attachments
 




Is a Supplemental Form 8 (Open Positions) attached?


YES




 
 




Date of disclosure:


20 NOVEMBER 2018




Contact name:


Craig Horsley




Telephone number:


+44(141) 245 7736




 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
 
 
 
 
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
 
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
 
 
4.   KEY INFORMATION
 




Identity of person whose open positions are being disclosed:


Morgan Stanley MUFG Securities Co., Ltd.




Name of offeror/offeree in relation to whose relevant securities the disclosure relates:


Takeda Pharmaceutical Company Limited




 
2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
 
 




Class of relevant security


Product Description e.g call option


Written or Purchased


Number of Securities to which option or derivative relates


Exercise Price Per Unit (USD)


Type


Expiry Date




 Ordinary


 PUT


PURCHASED


 125,000


4507.0000 JPY


 European


13/12/2019




 Ordinary


 CALL


PURCHASED


 125,000


4507.0000 JPY


 European


13/12/2019




 Ordinary


 PUT


PURCHASED


 60,000


4596.0000 JPY


 European


14/06/2019




 Ordinary


 CALL


PURCHASED


 60,000


4596.0000 JPY


 European


14/06/2019




 
 
 
 
3.         AGREEMENTS TO PURCHASE OR SELL ETC.
 




Full details should be given so that the nature of the interest or position can be fully understood:




 
 
 
 
 




 
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.
 
The currency of all prices and other monetary amounts should be stated.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOEANFEALFPFEF